FDA advisers voted to loosen restrictions on BPC-157 and TB-500, against their own agency's scientists
Over two days, the FDA's Pharmacy Compounding Advisory Committee voted to recommend that US compounding pharmacies be allowed to prepare BPC-157, KPV, TB-500 and MOTS-c, then on the second day added Epitalon and Semax. Emideltide was the only compound rejected. The votes were narrow, 8 to 6 with one abstention for the first three, and 7 to 5 with two abstentions for MOTS-c. FDA's own career scientists had reviewed all seven and recommended against every one, citing immunogenicity, peptide-related impurities and limited safety information. Agency staff also raised a more basic obstacle: without universally accepted chemical definitions for these substances, identity and quality cannot be reliably assessed in the first place.
What this actually means
Nothing changes in the UK. This is a US committee making a US recommendation, and it has no bearing on the MHRA. BPC-157 and TB-500 remain unlicensed medicines here, and supplying them for human use is still prohibited.
It also is not approval, even in America, and that distinction is already being blurred. Three separate legal events are being reported as one: removal from the FDA's safety-concern category, a recommendation from this panel, and actual placement on the compoundable list, which requires formal rulemaking and typically takes 8 to 12 months. The FDA is not bound by what the panel said.
And a recommendation for compounding is nowhere near the standard for drug approval. It does not mean these compounds have been shown to work. None of them has the large controlled human trials that approval requires, which is exactly why the agency's own reviewers said no. Expect the vote to be sold to you as vindication over the coming weeks. It is not that.
What this is. A dated, sourced note on something that changed. Peptide Register is an independent reference: it sells nothing, carries no advertising, and takes no money from any company selling any compound it covers. This is not medical advice. If a change affects a medicine you are prescribed, speak to your doctor or pharmacist rather than acting on something you read here.